ACADIA Pharmaceuticals (ACAD) Projected to Post Quarterly Earnings on Tuesday

ACADIA Pharmaceuticals (NASDAQ:ACAD) is projected to post its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect the company to announce earnings of $0.0580 per share and revenue of $295.5080 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.02). ACADIA Pharmaceuticals had a net margin of 34.30% and a return on equity of 9.61%. The company had revenue of $268.10 million for the quarter, compared to analyst estimates of $280.25 million. During the same period in the previous year, the business posted $0.11 EPS. The firm’s quarterly revenue was up 9.7% on a year-over-year basis. On average, analysts expect ACADIA Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

ACADIA Pharmaceuticals Trading Down 2.6%

ACAD stock opened at $25.87 on Friday. The firm’s 50-day moving average is $23.74 and its two-hundred day moving average is $23.23. The company has a market capitalization of $4.43 billion, a price-to-earnings ratio of 11.76, a price-to-earnings-growth ratio of 17.94 and a beta of 0.80. ACADIA Pharmaceuticals has a 52 week low of $19.69 and a 52 week high of $28.35.

Insiders Place Their Bets

In related news, EVP Elizabeth H.Z. Thompson sold 16,558 shares of the company’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $26.13, for a total value of $432,660.54. Following the completion of the sale, the executive vice president directly owned 18,994 shares in the company, valued at approximately $496,313.22. This represents a 46.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider James Kihara sold 5,401 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total transaction of $114,393.18. Following the transaction, the insider directly owned 24,509 shares in the company, valued at $519,100.62. The trade was a 18.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 26,797 shares of company stock valued at $652,474 over the last ninety days. Corporate insiders own 26.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ACAD. Cetera Investment Advisers lifted its holdings in ACADIA Pharmaceuticals by 2.7% in the 4th quarter. Cetera Investment Advisers now owns 16,355 shares of the biopharmaceutical company’s stock worth $437,000 after purchasing an additional 436 shares during the last quarter. J.W. Cole Advisors Inc. grew its holdings in ACADIA Pharmaceuticals by 2.5% during the fourth quarter. J.W. Cole Advisors Inc. now owns 20,632 shares of the biopharmaceutical company’s stock valued at $551,000 after purchasing an additional 501 shares during the last quarter. Vise Technologies Inc. grew its holdings in ACADIA Pharmaceuticals by 4.0% during the third quarter. Vise Technologies Inc. now owns 15,367 shares of the biopharmaceutical company’s stock valued at $328,000 after purchasing an additional 585 shares during the last quarter. Thrivent Financial for Lutherans raised its position in shares of ACADIA Pharmaceuticals by 0.7% in the second quarter. Thrivent Financial for Lutherans now owns 91,067 shares of the biopharmaceutical company’s stock valued at $1,964,000 after purchasing an additional 626 shares during the period. Finally, Advyzon Investment Management LLC raised its position in shares of ACADIA Pharmaceuticals by 7.4% in the fourth quarter. Advyzon Investment Management LLC now owns 11,612 shares of the biopharmaceutical company’s stock valued at $310,000 after purchasing an additional 798 shares during the period. Institutional investors and hedge funds own 96.71% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Stifel Nicolaus boosted their target price on ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the stock a “hold” rating in a report on Tuesday, July 21st. BMO Capital Markets lifted their price target on ACADIA Pharmaceuticals from $34.00 to $36.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 21st. Citigroup boosted their target price on shares of ACADIA Pharmaceuticals from $32.00 to $35.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Canaccord Genuity Group increased their price target on shares of ACADIA Pharmaceuticals from $32.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Finally, Bank of America restated a “buy” rating and set a $14.50 price target on shares of ACADIA Pharmaceuticals in a report on Wednesday. Thirteen analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $32.31.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.